Valeant price target lowered to $76 from $80 at RBC Capital

theflyonthewall.com

RBC Capital reduced its price target on Valeant to reflect an earlier than expected launch of a generic version of Valeant's Zovirax ointment. The firm, however, believes that Valeant's 2013 EPS guidance may remain unchanged, partly due to acquisitions by the company. RBC Capital maintains an Outperform rating on the shares.

Rates

View Comments (0)